- Home
- PMN vs UNCY Comparison
PMN vs UNCY Comparison
Compare PMN & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMN
- UNCY
- Stock Information
- Founded
- PMN 2004
- UNCY 2016
- Country
- PMN Canada
- UNCY United States
- Employees
- PMN N/A
- UNCY N/A
- Industry
- PMN Pharmaceuticals and Biotechnology
- UNCY Biotechnology: Pharmaceutical Preparations
- Sector
- PMN Health Care
- UNCY Health Care
- Exchange
- PMN Nasdaq
- UNCY Nasdaq
- Market Cap
- PMN 32.3M
- UNCY 31.9M
- IPO Year
- PMN N/A
- UNCY 2021
- Fundamental
- Price
- PMN $0.98
- UNCY $0.46
- Analyst Decision
- PMN
- UNCY Strong Buy
- Analyst Count
- PMN 0
- UNCY 4
- Target Price
- PMN N/A
- UNCY $5.50
- AVG Volume (30 Days)
- PMN 89.7K
- UNCY 1.9M
- Earning Date
- PMN 11-26-2024
- UNCY 11-13-2024
- Dividend Yield
- PMN N/A
- UNCY N/A
- EPS Growth
- PMN N/A
- UNCY N/A
- EPS
- PMN N/A
- UNCY N/A
- Revenue
- PMN N/A
- UNCY N/A
- Revenue This Year
- PMN N/A
- UNCY N/A
- Revenue Next Year
- PMN N/A
- UNCY N/A
- P/E Ratio
- PMN N/A
- UNCY N/A
- Revenue Growth
- PMN N/A
- UNCY N/A
- 52 Week Low
- PMN $0.92
- UNCY $0.20
- 52 Week High
- PMN $3.10
- UNCY $1.82
- Technical
- Relative Strength Index (RSI)
- PMN 42.82
- UNCY 48.64
- Support Level
- PMN $0.97
- UNCY $0.41
- Resistance Level
- PMN $1.08
- UNCY $0.55
- Average True Range (ATR)
- PMN 0.13
- UNCY 0.06
- MACD
- PMN -0.00
- UNCY -0.01
- Stochastic Oscillator
- PMN 1.67
- UNCY 23.47
About PMN ProMIS Neurosciences Inc. (ON)
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine is based on the use of two complementary techniques. The company applies its thermodynamic, computational discovery platform-ProMIS and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's lead drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury.